Navigation Links
Study Published in Journal of Vascular Surgery Confirms Superiority of Artegraft BCA to Cuffed ePTFE for Hemodialysis Access
Date:7/20/2011

NORTH BRUNSWICK, N.J., July 20, 2011 /PRNewswire/ -- Artegraft, Inc. announces that a three-year prospective, randomized clinical study published in the June 2011 issue of the Journal of Vascular Surgery confirms the superiority of Artegraft® Bovine Carotid Artery vascular grafts (BCA) to cuffed ePTFE grafts. Conducted at Massachusetts General Hospital, the study concluded that the BCA graft had significantly higher primary and assisted patency rates than the ePTFE graft, making Artegraft an excellent option for patients on hemodialysis who are not eligible for native arteriovenous fistulas.

The study results concluded that the Overall Primary Patency Rate at one year was 60 percent for Artegraft and 10 percent for ePTFE. For Assisted Primary Patency Rate at one year, Artegraft was 60 percent and ePTFE was 20 percent, according to the study results. After two years, the Assisted Primary Rate was 40 percent for Artegraft and 14 percent for ePTFE. Study results also concluded that there were less thrombosis and fewer interventions with the Artegraft BCA, as well as no pseudoaneurysms.

"The study validates the results that leading surgeons who have used Artegraft have experienced for 40 years," said Richard A. Gibson, President and Chief Executive Officer, Artegraft. "Our BCA grafts have been successfully used in thousands of patients. Its success is due to many factors, including the superior placement characteristics of Artegraft and that it is naturally accepted by the body."

A natural collagen vascular graft, Artegraft is processed to enhance long-term patency and
provide a tightly woven, cross-linked conduit that is flexible and compliant. It is especially ideal to utilize in patients with failed or immature native fistula; interposition in a fistula with a ruptured aneurysm; groin access; low protein conditions in which seroma formation may occur; and patients with hypotension. Patients suffering from an infected ePTFE graft or recurrent clotting with a synthetic graft or fistula are candidates for Artegraft, as well.

About Artegraft

Incorporated in 1993, Artegraft Inc. offers surgeons a biological alternative to synthetic grafts.  Artegraft's natural collagen matrix has proven long-term patency advantages over ePTFE and other synthetic graft materials. Artegraft is also positioned as an alternative to a non-viable autogenous fistula. Artegraft was the first vascular graft approved by the FDA in 1970 and has been in continuous clinical use for over 35 years. 

For more information, visit www.artegraft.com


'/>"/>
SOURCE Artegraft, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. DecisionView StudyOptimizer 4.3™ Enhances Market-Leading Enrollment Optimization Solution With Greater Visibility Into Site Performance and Cost Forecasting
2. Upsher-Smith Laboratories Begins Phase III Study of Intranasal Midazolam for Rescue Treatment of Seizure Clusters in Epilepsy Patients
3. Bayer Study Reveals Gaps in Perception of Veterinary Care Between Vets and Pet Owners
4. Study Confirms that OrbusNeichs Genous™ Stent Effectively Captures Circulating Endothelial Progenitor Cells to Accelerate Re-Endothelialization and Decrease Thrombogenicity
5. Metamark Genetics Announces Cancer Cell Study Highlighting Discovery of Key Molecules that Drive Progression of Malignant Melanoma in Humans
6. Exenatide tQT Study Showed No Prolongation of QT Interval
7. PicoCal Inc. Announces Completion of NSF Funded Research With a Number of New Products, Patents, Publications of Innovative Devices for Topographical Imaging, Thermomechanical Analysis, the Study of Local Mechanical Properties and High Throughput Ap
8. Edward Breast Imaging Expert Lauds Swedish Mammography Study
9. Council on Competitiveness Showcases Power of High Performance Computing in Case Study with GNS Healthcare
10. Endo Announces Topline Results From Phase 2 Study of Axomadol in Chronic Low Back Pain
11. Auxilium Pharmaceuticals Announces Results from Three Year CORDLESS Extension Study in Dupuytrens Contracture
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... Cohen Veterans Bioscience and Early Signal Foundation announce a ... sensors for real-time monitoring of patients with trauma-related and ... focused on disruptive health solutions for rare disorders and ... record and integrate behavioral, cognitive, physiological and contextual data. ... ...
(Date:9/25/2017)... R.I. , Sept. 25, 2017  EpiVax, ... assessment, vaccine design, and immune-engineering today announced the ... on the development of personalized therapeutic cancer vaccines. ... has provided exclusive access to enabling technologies to ... Eng., MBA will lead EpiVax Oncology as Chief ...
(Date:9/19/2017)... 2017 HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, ... three leadership team developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has ...
Breaking Medicine Technology:
(Date:10/13/2017)... Nevada (PRWEB) , ... October 13, 2017 , ... ... Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil ... required and providing a CBD form that can be easily incorporated into liquid products, ...
(Date:10/13/2017)... SAN LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... with Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for ... mean is the 90-day elimination period, when the family pays for care, is often ...
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released a ... books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture of ... have tossed it off as mere rubbish, but Yisrayl Hawkins says that is because ...
(Date:10/13/2017)... ... 2017 , ... “America On The Brink”: the Christian history of the United ... the creation of published author, William Nowers. Captain Nowers and his wife, Millie, ... spent thirty years in the Navy. Following his career as a naval aviator ...
(Date:10/12/2017)... WAUSAU, Wis. (PRWEB) , ... October 12, 2017 ... ... formulated standard products to meet the demand of today’s consumer and regulatory authorities ... team of probiotic experts and tested to meet the highest standard. , ...
Breaking Medicine News(10 mins):